Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Founding Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Gary Rieschel
Founder and Managing Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Bonnie Wang
Principal
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Past deals in Health Care
Prime Lifescience
Seed Round in 2023
Prime Lifescience is a developer of a big data platform that focuses on life sciences. The company is dedicated to establishing a health lifecycle big data collaboration network through digital technology innovation and extensive use of artificial intelligence. They offer a digital smart health community, a digital intelligent clinical research accelerator, and a live big data platform as part of their offering.
Wecare Probiotics
Series D in 2023
Wecare Probiotics is a national high-tech enterprise specializing in the R & D, production, and application of probiotic strains.
Tourmaline Bio
Post in 2023
Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients with immune diseases. Its primary product candidate, TOUR006, is a fully human monoclonal antibody that targets interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The company leverages over twenty years of clinical and commercial experience associated with the anti-IL-6 and anti-IL-6 receptor antibody class, which has effectively treated over a million patients suffering from a range of autoimmune conditions. Tourmaline Bio is committed to addressing the needs of individuals with life-altering immune diseases through its innovative therapeutic approaches.
Complete Omics
Series A in 2023
Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.
SinoUnited Health
Series C in 2023
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
Fushoukang
Series C in 2022
Fushoukang is a home medical care services organization. They offer home medical care, nursing, and rehabilitation services. They provide long term services, institutional care, home care, smart home beds, and hospitcal escorts for the healthy self care elderly, semin disabled elderly , sick elderly, and demented elderly, and more services.
Boulder Care
Series B in 2022
Boulder is a digital health platform expanding access to effective treatment for opiate use. We aim to move the behavioral health industry forward by offering dramatically better experiences for patients and their care teams.
Prime Lifescience
Seed Round in 2022
Prime Lifescience is a developer of a big data platform that focuses on life sciences. The company is dedicated to establishing a health lifecycle big data collaboration network through digital technology innovation and extensive use of artificial intelligence. They offer a digital smart health community, a digital intelligent clinical research accelerator, and a live big data platform as part of their offering.
Ceptur Therapeutics
Series A in 2022
Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.
Ruining Bio
Series A in 2022
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
Structure Therapeutics
Series B in 2021
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.
Berry Oncology
Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
SinoUnited Health
Series C in 2021
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
IntoCare
Secondary Market in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Wuli Planet
Series A in 2020
Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.
Structure Therapeutics
Series A in 2020
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.
Berry Oncology
Series A in 2020
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
SinoUnited Health
Series C in 2019
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
SinoUnited Health
Series B in 2019
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
Structure Therapeutics
Series A in 2019
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.
CardiaLen
Series B in 2018
CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.
IntoCare
Series B in 2018
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Wuli Planet
Seed Round in 2018
Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.
Qiagen Suzhou Translational Medicine
Series A in 2017
QIAGEN Suzhou is an innovative start-up providing precision medicine solutions.
Twine Health
Series A in 2017
Twine Health, Inc. is a healthcare technology company that specializes in a cloud-based platform aimed at chronic disease management. The platform facilitates collaborative care by integrating tools for shared decision-making, self-tracking, and communication between patients and their healthcare providers. Patients can co-create personalized care plans with their care teams, which may include physicians, nurses, family members, and health coaches. This collaborative approach is designed to enhance patient engagement and self-efficacy, ultimately leading to better health outcomes and reduced healthcare costs. Established in 2012 and based in Cambridge, Massachusetts, Twine Health was developed at the MIT Medical Lab and operates as a subsidiary of Fitbit, Inc. since 2018.
LIH Investment & Management
Series A in 2017
LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.
Junhetang
Series B in 2016
Junhetang is an operator of traditional Chinese medicine clinics. It is a chain of traditional Chinese medicine (TCM) healthcare management and service centers. Junherang has combined TCM culture, rare and renowned TCM experts, personalized medical services and convenient internet services to establish an innovative TCM service network with education, training, medical care, health maintenance and IT service functions. The company operates a chain of clinics that offers traditional Chinese medicines and therapies including herbal medicine, acupuncture, massage, exercise and dietary therapies. Headquartered in Nanjing, an ancient city in China, Junhetang is now expanding its business in different cities in China, such as Nanjing, Shanghai, Shenzhen, Chengdu, Taiyuan and so on.
LIH Investment & Management
Series A in 2016
LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.
JHT TCM Clinics
Series B in 2016
JHT TCM Clinics
Junhetang
Series B in 2015
Junhetang is an operator of traditional Chinese medicine clinics. It is a chain of traditional Chinese medicine (TCM) healthcare management and service centers. Junherang has combined TCM culture, rare and renowned TCM experts, personalized medical services and convenient internet services to establish an innovative TCM service network with education, training, medical care, health maintenance and IT service functions. The company operates a chain of clinics that offers traditional Chinese medicines and therapies including herbal medicine, acupuncture, massage, exercise and dietary therapies. Headquartered in Nanjing, an ancient city in China, Junhetang is now expanding its business in different cities in China, such as Nanjing, Shanghai, Shenzhen, Chengdu, Taiyuan and so on.
MedSci
Series A in 2015
MedSci specializes in delivering strategies, solutions, and services to the pharmaceutical, biotech, and medical device sectors, as well as the consumer healthcare industry. The company operates a clinical services platform that offers an online resource for medical research, along with clinical and academic translation services. Additionally, MedSci provides a range of services, including clinical research, medical affairs, marketing, and consulting, aimed at enhancing the quality of healthcare for its clients.
BBI Life Sciences
Post in 2015
BBI Life Sciences Corporation is a prominent investment holding company based in Shanghai, China, specializing in the development, manufacturing, and sale of a wide range of life sciences products and services. The company operates through five segments: DNA Synthesis Products, Genetic Engineering Services, Life Science Research Consumables, Protein and Antibody Related Products and Services, and Third Party Detection. Its offerings include oligonucleotide synthesis and gene synthesis products for molecular biology and medical research, DNA sequencing, gene cloning, and various laboratory consumables. Additionally, BBI provides services related to protein extraction and analysis, as well as custom antibody production. The company serves a diverse clientele that includes universities, research institutes, hospitals, and pharmaceutical firms, both domestically and internationally. BBI Life Sciences has established a strong market presence with its well-recognized brands and is noted for its quality products and competitive pricing. Founded in 2013, BBI Life Sciences has quickly become a leading provider in the life sciences research sector in China.
Mitralign
Series E in 2015
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
WeDoctor
Venture Round in 2014
WeDoctor is a leading medical health technology platform established in 2010 by Liao Jieyuan and his team. The platform aims to enhance access to healthcare by integrating technology into medical services, thereby promoting an ecological upgrade in medical insurance. WeDoctor provides a comprehensive health management system that combines online and offline services, catering to both general and specialist medical needs. Through its mobile application, users can easily access various medical services, including scheduling appointments, reading medical advice from doctors, and evaluating healthcare providers. This innovative approach positions WeDoctor as a health gatekeeper for millions of families, streamlining the process of obtaining essential medical care.
JHT TCM Clinics
Series A in 2013
JHT TCM Clinics
Aeonmed Medical Treatment
Series A in 2010
Aeonmed Medical Treatment is a manufacturer and supplier specializing in operating theatre and intensive care unit (ICU) devices. The company focuses on developing a range of medical equipment, including anesthesia machines, operating beds, infusion pumps, mechanical ventilation systems, and nebulizers. Additionally, Aeonmed offers comprehensive medical treatment system solutions that encompass anesthesia and operation support, emergency and critical care, and medical engineering equipment. Their product offerings also include five major medical system solutions, such as laminar flow monitoring and centralized gas supply. Since its inception, Aeonmed has prioritized clinical demands and innovation, resulting in a robust portfolio of over 600 authorized patents, with more than 400 being invention patents, reflecting a commitment to advancing healthcare technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.